Company Research Report: Iktos
Company Overview
Name: Iktos
Mission: Unlock the Future of Molecular Discovery. Iktos leverages cutting-edge AI and robotics to transform drug discovery.
Founded: 2016
Founders:
- Yann Gaston-Mathé
- Quentin Perron
- Nicolas Do Huu
Key People:
- Yann Gaston-Mathé: Co-Founder & CEO | Board Member
- Quentin Perron: Co-Founder & CSO | Board Observer
- Nicolas Do Huu: Co-Founder & CTO | Board Member
- Roman Fleck: Chairman of the Board
- Bertrand Ducrey: Board Member
- Nadiya Ishnazarova: Board Member
- Fabien Collangettes: Board Observer
- Christian Uhrich: Board Observer
- Vincent Gerusz: Board Observer
- Jérôme Dhamelincourt: Board Observer
Headquarters: 65 rue de Prony, 75017 Paris, France
Number of Employees: No information is available
Revenue: No information is available
Company Expertise: Known for pioneering AI and robotics in drug discovery, integrating generative AI with automated synthesis and testing to create fully autonomous labs.
Products
Makya - Generative AI Platform
Description: A generative AI SaaS platform designed for creating diverse, novel, and medchem-like molecules.
Key Features:
- Generative AI technology for de novo drug design
- Focus on synthetic accessibility
- Multi-parametric optimization
- Inclusion of 3D constraints
Spaya - AI-Driven Retrosynthesis Platform
Description: An AI-driven platform that identifies feasible synthetic routes, converting target compounds into commercially available starting materials.
Key Features:
- Real-time display of retrosynthetic routes
- Customizable synthesis steps and constraints
- Integration with various data providers
Iktos Robotics - Autonomous Lab
Description: Automation platform that manages compound synthesis from raw material ordering to chemical synthesis execution.
Key Features:
- Fully automated synthesis and analysis
- High-throughput data generation and iteration
- Ongoing integration of reaction monitoring, purification, and biological testing
Recent Developments
August 7, 2024
Development: Iktos announces the acquisition of Synsight.
February 5, 2024
Development: Iktos announces the appointment of Roman Fleck as Chairman.
March 5, 2024
Development: Iktos and Elsevier announce their partnership to deliver a predictive retrosynthesis and synthetic accessibility platform.
Partnering and Collaborations
Iktos collaborates with pharmaceutical and biotech companies to drive innovation in drug discovery. Their Integrated Drug Discovery collaborations leverage AI and robotics platforms to accelerate new drug candidate development.
Pipeline
Target: MTHFD2
- Therapeutic Areas: Inflammation autoimmune diseases
- Preclinical Candidate: IKT525
Confidential Targets:
- Therapeutic Areas: Oncology (three separate confidential targets), Immuno-oncology
- Development Stages: Hit Discovery, Hit-to-Lead, Lead Optimization
Key Customers and Projects
Collaborations: Over 60 successful collaborations with leading pharmaceutical, biotech, and academic institutions.
Technologies and Innovations
Makya - Generative AI
Role: Novels molecule design with high synthetic feasibility.
Spaya - Retrosynthesis AI
Role: Determines efficient synthetic routes for designed compounds.
Iktos Robotics - Autonomous Lab
Role: High-speed synthesis of molecules for rapid iteration and fast development of drug candidates.
Marketing and Outreach
News and Articles: Latest updates available on:
- Acquisition of Synsight
- Appointment of Roman Fleck
- Partnership with Elsevier
Contact Information:
- Address: 65 rue de Prony, 75017 Paris, France
- Phone: 09 73 58 45 48
- Email: contact@iktos.com
Stay informed with Iktos by subscribing to their newsletter to receive the latest updates on AI-driven drug discovery.
